Revolution Medicines (RVMD) News Today $36.63 -0.64 (-1.72%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$37.25 +0.62 (+1.69%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RVMD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period 55,488 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by XTX Topco LtdAugust 1 at 7:46 AM | marketbeat.comTD Asset Management Inc Acquires 44,490 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)August 1 at 7:10 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Makes New $2.34 Million Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)July 31 at 7:17 AM | marketbeat.comRevolution Medicines (RVMD) Projected to Post Earnings on WednesdayJuly 31 at 6:34 AM | marketbeat.comRevolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025July 30 at 4:05 PM | globenewswire.comS&CO Inc. Makes New Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)July 29, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives $68.91 Consensus Price Target from AnalystsJuly 26, 2025 | americanbankingnews.comRevolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective InhibitorJuly 24, 2025 | globenewswire.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Sold by Victory Capital Management Inc.July 24, 2025 | marketbeat.comRevolution Medicines Announces FDA Breakthrough Therapy Designation for ElironrasibJuly 23, 2025 | globenewswire.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Consensus Recommendation of "Buy" from AnalystsJuly 21, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Arizona State Retirement SystemJuly 19, 2025 | marketbeat.comBank of New York Mellon Corp Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)July 18, 2025 | marketbeat.comGoldman Sachs Initiates Coverage of Revolution Medicines (RVMD) with Buy RecommendationJuly 15, 2025 | msn.comRevolution Medicines (NASDAQ:RVMD) Now Covered by Analysts at The Goldman Sachs GroupJuly 15, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Acquired by Edgestream Partners L.P.July 14, 2025 | marketbeat.comRevolution Medicines and Iambic Announce Technology and Research ...July 11, 2025 | nasdaq.comRevolution Medicines and Iambic Therapeutics Announce ... - NasdaqJuly 11, 2025 | nasdaq.comRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug CandidatesJuly 9, 2025 | finance.yahoo.comRevolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug CandidatesJuly 9, 2025 | globenewswire.comAllspring Global Investments Holdings LLC Trims Position in Revolution Medicines, Inc. (NASDAQ:RVMD)July 9, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Acquires 27,982 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)July 8, 2025 | marketbeat.comRevolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid TumorsJuly 6, 2025 | msn.comRevolution Medicines, Inc. (NASDAQ:RVMD) Position Boosted by WCM Investment Management LLCJuly 3, 2025 | marketbeat.comRevolution Medicines and Summit Therapeutics Announce Clinical Collaboration to Evaluate RAS (ON) Inhibitors in Combination with Ivonescimab for Solid Tumors - NasdaqJuly 2, 2025 | nasdaq.comLeerink Partnrs Issues Optimistic Estimate for RVMD EarningsJuly 2, 2025 | marketbeat.comRevolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant TumorsJune 30, 2025 | globenewswire.comLunate Capital Ltd Invests $77.66 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)June 29, 2025 | marketbeat.comQ3 EPS Estimate for Revolution Medicines Raised by AnalystJune 27, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Given Average Recommendation of "Buy" by AnalystsJune 26, 2025 | marketbeat.comRevolution Medicines' (RVMD) Buy Rating Reiterated at GuggenheimJune 25, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines' Daraxonrasib Receives FDA Breakthrough Therapy Designation for Metastatic Pancreatic Ductal Adenocarcinoma | NasdaqJune 24, 2025 | nasdaq.comNeedham & Company LLC Reiterates "Buy" Rating for Revolution Medicines (NASDAQ:RVMD)June 24, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Gap Down - Here's What HappenedJune 24, 2025 | marketbeat.comRoyalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drugJune 24, 2025 | reuters.comRevolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted CancersJune 24, 2025 | globenewswire.comRevolution Medicines, Inc.: Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS ...June 23, 2025 | finanznachrichten.deRevolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 MutationsJune 23, 2025 | globenewswire.comSG Americas Securities LLC Acquires 15,164 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)June 22, 2025 | marketbeat.comRevolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In HistoryJune 19, 2025 | seekingalpha.comGAMMA Investing LLC Purchases 20,696 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)June 18, 2025 | marketbeat.comHarbor Capital Advisors Inc. Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)June 13, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)June 1, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Receives Average Recommendation of "Buy" from AnalystsJune 1, 2025 | marketbeat.com22,725 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Jefferies Financial Group Inc.May 30, 2025 | marketbeat.comVoloridge Investment Management LLC Has $2.09 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)May 30, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Shares Up 3.9% - Should You Buy?May 29, 2025 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's WhyMay 28, 2025 | marketbeat.comPolar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)May 28, 2025 | marketbeat.com Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address RVMD Media Mentions By Week RVMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVMD News Sentiment▼1.010.63▲Average Medical News Sentiment RVMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVMD Articles This Week▼67▲RVMD Articles Average Week Get Revolution Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for RVMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BNTX News SMMT News INSM News TEVA News GMAB News MRNA News RDY News QGEN News VTRS News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVMD) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
